In 537 virally suppressed African adults with HIV and adherence challenges, injectable cabotegravir–rilpivirine every 8 weeks was noninferior to oral dolutegravir for viral load <50 at 48 weeks (91.0% vs 89.2%); confirmed virologic failure 1.9% vs 0%.
RCTn = 540
Cresswell et al. Long-Acting HIV Therapy in African Adults with Adherence Challenges